Eli Lilly says new Omvoh analyses show corticosteroid-free disease control in ulcerative colitis and deep remission in Crohn’s at one year

Eli Lilly (LLY) reported new composite outcomes analyses suggesting patients with moderately to severely active ulcerative colitis and Crohn’s disease achieved stringent, corticosteroid-free treatment goals after one year on its therapy Omvoh, also known by the generic name mirikizumab-mrkz.

In the update, Lilly said patients treated with Omvoh (mirikizumab-mrkz) reached “comprehensive corticosteroid-free disease control” in ulcerative colitis at one year. In Crohn’s disease, the company said patients achieved “corticosteroid-free deep remission” at the same one-year time point, using composite outcome measures that combine multiple signs of disease control into a single assessment.

Composite outcomes are designed to reflect more complete disease status rather than a single clinical metric. In inflammatory bowel disease, corticosteroid-free endpoints are often treated as a key objective because long-term steroid use can create significant risks, and clinicians generally prefer steroid-sparing regimens when possible.

The Omvoh update comes as competition in inflammatory bowel disease therapies continues to intensify, with multiple biologics and other immune-modulating options targeting specific pathways involved in inflammation. For Lilly, improving the story around durable outcomes and reduced reliance on steroids can be important for differentiating a drug in a crowded segment and for strengthening payer and guideline conversations.

While the company’s announcement emphasized results at the one-year mark, the posting did not provide additional granular details in the material reviewed here, such as the number of patients analyzed, specific response thresholds inside the composite measures, or the magnitude of differences versus any comparator.

Lilly also did not disclose, in the material provided for this review, whether the analyses came from a specific trial dataset, how strictly the patient groups were selected for the one-year assessment, or how adverse events and discontinuations weighed into the composite outcome conclusions.

Investors and clinicians typically watch for whether corticosteroid-free goals are durable and clinically meaningful, because that can affect treatment plans, sequencing decisions, and how outcomes are translated into real-world practice.

Next, the market is likely to focus on whether Lilly provides more detail around the study basis for the composite outcomes, including the trial source, statistical framing, and any additional timepoints beyond one year, as well as how these measures relate to other endpoints already tracked by regulators and clinicians.